Clinical practice guideline for clozapine use in patients with COVID‐19

IF 0.4 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2023-01-01 DOI:10.1002/pnp.779

S. Ansari, Marlene Kelbrick, Gabriela Paduret, N. Diaz, Rose Menzel, R. Rogers, Claire Wareham, Chris Griffiths, Sue Jugon, Katy Tidy, Sara Johnson, Nick Mann, James Tanner, Timothy Millward, Shahid Latif

引用次数: 0

Abstract

National and local guidelines focus mainly on clozapine monitoring frequency, and actions based on full blood count results. Prescribing clozapine in the context of COVID‐19‐positive patients brings a complexity of challenge beyond this. In this article the authors put forward an example of a practical clinical guideline in this regard.

查看原文本刊更多论文

COVID-19患者使用氯氮平的临床实践指南

国家和地方指南主要关注氯氮平监测频率，以及基于全血计数结果的行动。在COVID-19阳性患者的情况下开具氯氮平处方带来了更为复杂的挑战。在这篇文章中，作者提出了一个实用的临床指南的例子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.